Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab. (Q51028676)

27 March 2018

title

Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab. (English)

1 reference

27 March 2018

12

Stanley C Jordan

1 reference

27 March 2018

author name string

Shili Ge

1

1 reference

27 March 2018

Andy Pao

2

1 reference

27 March 2018

Ashley Vo

3

1 reference

27 March 2018

Nathan Deer

4

1 reference

27 March 2018

Artur Karasyov

5

1 reference

27 March 2018

Anna Petrosyan

6

1 reference

27 March 2018

Joseph Kahwaji

7

1 reference

27 March 2018

Marina Lukovsky

8

1 reference

27 March 2018

Ning-Ning Chai

9

1 reference

27 March 2018

Angela Aguiluz

10

1 reference

27 March 2018

James Mirocha

11

1 reference

27 March 2018

Mieko Toyoda

13

1 reference

27 March 2018

publication date

28 November 2010

1 reference

27 March 2018

published in

Transplant Immunology

1 reference

27 March 2018

volume

24

1 reference

27 March 2018

issue

3

1 reference

27 March 2018

page(s)

142-148

1 reference

27 March 2018

Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Rituximab and intravenous immune globulin for desensitization during renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Rituximab as treatment for refractory kidney transplant rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Rituximab in highly sensitized kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Impact of rituximab therapy for treatment of acute humoral rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Incidence of JC-virus replication after rituximab therapy in solid-organ transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

The AJT report: news and issues that affect organ and tissue transplantation. Wrestling with positive cross-matches. A look at some of the newer desensitization therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Cellular immune responses to cytomegalovirus in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Co-infection of polyomavirus-BK and cytomegalovirus in renal transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Clinical significance of peripheral blood Epstein-Barr viral load monitoring using polymerase chain reaction in renal transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Campath-1H induction and the incidence of infectious complications in adult renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

Human natural killer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.11.006

10.1016/J.TRIM.2010.11.006

7 January 2021

Identifiers

DOI

1 reference

27 March 2018

1 reference

27 March 2018